THE INDIAN JOURNAL OF CANCER

CONTENTS

EDITORIAL
Indian needs stricter implementation.....

Pankaj Chaturvedi 129

ORIGINAL ARTICLES
Point of sale tobacco advertisements in India
Chaudhry S, Chaudhry S, Chaudhry K 131

Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: A single institutional experience
Biswas G, Khadwal A, Arora B, Bhagwat R, Banavali SD, Nair CN, Pai SK, Kurkure PA, Parikh PM 137

In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy
Pathak KA, Juvkar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D’Cruz AK, Parikh PM 142

Validation of the University of Washington quality of life questionnaires for head and neck cancer patients in India
D’cruz AK, Yueh B, Das AK, Mcdowell JA, Chaukar DA, Ernest AW 147

CASE REPORT
Penile metastasis from rectal carcinoma
Murhekar KM, Majhi U, Mahajan V, Satheesan B 155

Radiotherapy-induced depigmentation in a patient with breast cancer
Anusheel Munshi, Sandeep Jain, Ashwini Budrukkar, Rakesh Jalali, Rajiv Sarin 157

AUTHOR INDEX - 2007

159

TITLE INDEX - 2007

161

INSTRUCTIONS FOR CONTRIBUTORS

162

The copies of the journal to members of the association are sent by ordinary post. The editorial board, association or publisher will not be responsible for non-receipt of copies. If any of the members wish to receive the copies by registered post or courier, kindly contact the journal’s / publisher’s office. If a copy returns due to incomplete, incorrect or changed address of a member on two consecutive occasions, the names of such members will be deleted from the mailing list of the journal. Providing complete, correct and up-to-date address is the responsibility of the members. Copies are sent to subscribers and members directly from the publisher’s address; it is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one cannot resale or give-away the copy for commercial or library use.
Radiotherapy-induced depigmentation in a patient with breast cancer

Anusheel Munshi, Sandeep Jain, Ashwini Budrukkar, Rakesh Jalali, Rajiv Sarin
Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India

Correspondence to: Dr. Anusheel Munshi, E-mail: anusheel8@hotmail.com

Abstract

Vitiligo is a common dermatological disorder. A middle-aged woman with preexisting vitiligo was diagnosed with breast carcinoma. After surgery and chemotherapy she received regional radiotherapy. Six months after the completion of radiotherapy she developed depigmentation in the irradiated area. This article discusses the etiology for this phenomenon and the literature in this regard.

Key words: Breast cancer, depigmentation, radiotherapy

Case Report

Vitiligo is a common skin disease that is reported to affect approximately 1% of the population worldwide.[1] Though not a life-threatening disease, the effects of vitiligo can be cosmetically and psychologically devastating, resulting in a low self-esteem and poor body image. The cause of this condition is uncertain but seems to be dependent on the interaction of genetic, immunological, and neurogenic factors.[2] Here, we report a case of a patient with vitiligo who developed depigmentation in the irradiated area after radiotherapy for breast cancer. We further discuss radiation-induced Koebner's phenomenon and its molecular mechanisms.

A 42-year-old perimenopausal woman presented with a painless lump of 3 months duration in her right breast. She had a 10-year history of untreated vitiligo on the lips and hands [Figure 1]. She was investigated and diagnosed as having an infiltrating ductal carcinoma of breast of stage T4NBM0. She received four cycles of neoadjuvant chemotherapy [cyclophosphamide, adriamycin, and 5-flourouracil (CEF) regime] which resulted in a partial clinical response. She underwent modified radical mastectomy followed by two cycles of adjuvant chemotherapy with CEF. Subsequently, she received adjuvant external-beam radiotherapy (EBRT) with tele-cobalt $\gamma$-rays to the chest wall and lymphatic drainage sites up to a dose of 45 Gy in 20 fractions over 4 weeks. She had hyperpigmentation and dry desquamation (grade 2 skin reactions, according to the common toxicity criteria) in the radiotherapy portal at the time of completion, which is an expected phenomenon. On the first follow-up after 6 months she complained of progressive white discoloration of the chest wall on the irradiated side. On examination, a depigmented macular area was found, which closely matched the bitangential radiotherapy portals [Figure 1]. On palpation, there was minimal skin atrophy, with no induration/fibrosis or change in skin elasticity.

Discussion

Vitiligo is an acquired hypomelanotic disorder characterized by circumscribed depigmented macules.

Figure 1: Depigmentation on the chest wall area which was treated by tangential radiotherapy beams
in the skin that result from the loss of functional melanocytes. Vitiligo patches can appear anywhere on the skin but common sites are usually around the body orifices, the genitals, or any sun-exposed areas, such as the face and hands.

Radiotherapy to the skin results in acute radiation injury to the skin, which is primarily a consequence of the loss of cells from the basal layer of the epidermis, and late injury, which is primarily a function of radiation effects on the vasculature. Commonly, this leads to hyperpigmentation of the skin at the completion of the radiotherapy course. Patients with collagen vascular diseases are known to have an increased radiation sensitivity of normal tissues to radiation damage, and cases of severe radiation skin sequelae, including severe fibrosis and/or necrosis, after breast or chest wall irradiation, have been reported. However, there is no evidence for increased severity of acute or chronic reactions in patients with vitiligo. Fresh depigmented lesions in the radiation portals have however been previously reported in patients with vitiligo who underwent radiation for breast cancer or other cancers. Our patient developed hypopigmentation 6 months after completion of radiotherapy, which is in contrast to the 2 months interval reported by Weizhen et al. Furthermore, depigmentation developed in the area irradiated by the tangential portals and not in the skin irradiated by the supraclavicular portal. This is explained by a principle of radiation physics, according to which skin sparing will be more with a direct incident portal compared to an oblique or tangential portal. Tangential portals cause increased electron build-up and consequently increase the dose delivered to the skin.

Cases of vitiligo following radiotherapy have been reported in patients with a history of vitiligo, being considered as Koebner’s phenomenon (KP). KP also known as the isomorphic response, is the development of preexisting skin disease following trauma to uninvolved skin. Many forms of environmental stress on skin have been reported as provoking factors for the KP; these include mechanical, chemical, thermal, and infectious stimuli; Ultra-Violet exposure; and various types of dermatitis. The suggested mechanism for this phenomenon is radiation-induced apoptosis of susceptible melanocytes. Loss of melanocytes in the irradiated skin has been demonstrated by Pajonk et al. and correlated with the dose-dependent decrease in the red/green and yellow/blue saturation and overall increase in brightness on colorimetry. Free radical-mediated damage, induced by radiotherapy, may be the initial pathogenic event in melanocyte degeneration in the irradiated skin. The early cell death of melanocytes in vitiligo is related to their increased sensitivity to the oxidative stress caused by irradiation, which may arise from complex processes of abnormal synthesis and processing of tyrosinase-related protein-1 and its interaction with calnexin. Keratinocyte apoptosis can cause lower expression of keratinocyte-derived factors, including stem cell factors and basic fibroblast growth factor. These factors might be responsible for passive melanocyte death, leading to their detachment and transepidermal elimination, and may explain the KP in the vitiligo patients. Recently, however, inhibition of thioredoxin reductase by the high extracellular calcium levels observed in the keratinocytes of vitiligo patients has been also proposed.

In patients with preexisting vitiligo, the risks and benefits of radiation therapy should be carefully weighed in order to prevent undesired cosmetic results, particularly in the setting of breast conservation therapy. Preserving the skin by using megavoltage beams and low dose per fraction might improve the cosmetic results of radiation therapy in patients with a history of vitiligo. Study of radiotherapy-induced KP may prove useful in understanding the pathophysiology of vitiligo since the etiology of the disease is still elusive. The choice of therapeutic modality in this radiosensitive group of patients should be made on a case-by-case basis.

References


Source of Support: Nil, Conflict of Interest: None declared.